Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine



Rating:

Share or cite this content

Citations should be made in the following way:
Thierry Berghmans (Belgium). From anti-PD1/L1 inhibitors to new immunotherapies. New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

Member's Comments

No comment yet.

Related content which might interest you: Novel targets and emerging therapies in MPM Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017 Proteases as tools for diagnosis and novel therapeutics Source: ERS Research Seminar 2015 Year: 2015 How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021 Identification of mechanism-specific biomarkers to guide development of the lung-selective inhaled pan-JAK inhibitor TD-8236 Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020 Targeting the arginase pathway: potential developments as new avenues for treatment Source: Annual Congress 2004 - Arginase: a novel target and marker for asthma? Year: 2004 TKIs: a new class of drugs in the management of lung cancer Source: Annual Congress 2011 - Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer Year: 2011 Targeting neuropeptide receptors by substance-P analogues identifies a strategy to develop novel anti-cancer therapies Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19 Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020 Year: 2020 Novel therapeutics for CF Source: International Congress 2019 – Future of cystic fibrosis care: insights from the Lancet Commission Year: 2019 Novel anti-angiogenic pharmacotherapy strategies Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 Potential of regulatory T-cell-based therapies in the management of severe COVID-19 Source: Eur Respir J, 56 (3) 2002182; 10.1183/13993003.02182-2020 Year: 2020 Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008 EGFR-inhibition: resistance mechanisms and new strategies Source: International Congress 2014 – Update on lung cancer biology for clinicians Year: 2014 New concepts in pulmonary oncology Source: ISSN=ISSN 1025-448x, ISBN=ISBN 978-1-904097-51-8, page=63 Year: 2007